8,561 results match your criteria Gastrointestinal Stromal Tumors


[Systematic surgery of retroperitoneal sarcomas : Imaging-guided planning of surgical strategy].

Authors:
M Ghadimi C J Bruns

Chirurg 2019 Apr 18. Epub 2019 Apr 18.

Klinik für Allgemein‑, Viszeral- und Tumorchirurgie, Uniklinikum Köln, Kerpener Straße 62, 50937, Köln, Deutschland.

Abdominal and retroperitoneal sarcomas (RPS) represent approximately 25-30% of all soft tissue sarcomas, if besides typical retroperitoneal tumors gastrointestinal stromal tumors (GIST) are also included. The surgical R0 en bloc resection with histopathologically free margins is basically the only potentially curative treatment procedure. When planning the surgical strategy, the histopathological subtype and tumor localization are pivotal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00104-019-0952-yDOI Listing
April 2019
2 Reads

Hepatic pleomorphic leiomyosarcoma after surgery for gastric gastrointestinal stromal tumor: a case report.

Surg Case Rep 2019 Apr 16;5(1):62. Epub 2019 Apr 16.

Department of General Surgical Science, Division of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Gunma University, 3-39-22 Showa-Machi, Maebashi, Gunma, 371-8511, Japan.

Background: Pleomorphic leiomyosarcomas (PLMSs) are extremely rare tumors. We present the first case of hepatic primary PLMS after surgery for gastric gastrointestinal stromal tumor (GIST).

Case Presentation: The patient was a 62-year-old man who was referred to our hospital for resection of a hepatic tumor arising after gastric GIST surgery that was resistant to imatinib and sunitinib. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-019-0622-9DOI Listing
April 2019
1 Read

Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo.

Anticancer Drugs 2019 Jun;30(5):475-484

Cytogenetics Laboratory, Carcinogenesis Institute, N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.

We showed recently that ethyl-2-amino-pyrrole-3-carboxylates (EAPCs) exhibit potent antiproliferative activities against a broad spectrum of soft tissue sarcoma and gastrointestinal stromal tumor (GIST) cell lines in vitro. The molecular mechanism of action was owing to inhibition of tubulin polymerization and induction of a robust G2/M cell-cycle arrest, leading to the accumulation of tumor cells in the M-phase and induction of apoptosis. Given that more than 50% of the patients with GISTs develop resistance to imatinib (IM) over the 2 years of IM-based therapy, we examined whether EAPCs exhibit activity against IM-resistant GISTs in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000753DOI Listing

Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry.

Clin Sarcoma Res 2019 2;9. Epub 2019 Apr 2.

2Portland VA Health Care System and Knight Cancer Institute, Oregon Health & Science University, Portland, OR USA.

Background: The use of imatinib, sunitinib, and regorafenib has transformed the treatment of advanced GIST. Sunitinib and regorafenib improve progression free-survival in the second (2L) and third (3L) line, respectively, compared with placebo. However, the impact of these agents on overall survival (OS) is unclear. Read More

View Article

Download full-text PDF

Source
https://clinicalsarcomaresearch.biomedcentral.com/articles/1
Publisher Site
http://dx.doi.org/10.1186/s13569-019-0114-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446260PMC
April 2019
5 Reads

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase 2 study.

Clin Cancer Res 2019 Apr 12. Epub 2019 Apr 12.

Department of Medical Oncology, Institut Bergonie

Purpose: CDKN2A loss is frequent in GIST and associated with aggressive outcome. Palbociclib is a CDK4 inhibitor with preclinical anti-tumor efficacy in tumors with P16/CDKN2A loss.

Methods: This is a multicenter single-arm phase 2 clinical trial assessing safety and efficacy of Palbociclib in patients (pts) with advanced GIST bearing CDKN2A gene loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3127DOI Listing

Coexistence of Gastric Cancer and Multiple Small Gastrointestinal Stromal Tumors: Report of a Unique Case and Review of the Literature.

Authors:
Helen J Trihia

Gastrointest Tumors 2019 Feb 21;5(3-4):63-67. Epub 2018 Dec 21.

Department of Pathology, "Metaxas" Cancer Hospital, Piraeus, Greece.

Background: In recent years, the synchronous occurrence of tumors of different histotypes arising in the same organ has been reported more frequently in the literature. The simultaneous development of adenocarcinoma and gastrointestinal stromal tumor (GIST) has been documented rarely.

Summary: The coexistence of primary gastric adenocarcinoma and GIST has been detected incidentally on gastric mucosa, serosa or occasionally intramurally, at surgery, or gastroscopy for other reasons. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422145PMC
February 2019
1 Read

Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants.

J Med Chem 2019 Apr 10. Epub 2019 Apr 10.

Institute of Biotechnology and Pharmaceutical Research , National Health Research Institutes , 35, Keyan Road , Zhunan Town , Miaoli County 350 , Taiwan R.O.C.

Drug resistance due to acquired mutations that constitutively activate c-KIT is a significant challenge in the treatment of patients with gastrointestinal stromal tumors (GISTs). Herein, we identified 1-(5-ethyl-isoxazol-3-yl)-3-(4-{2-[6-(4-ethylpiperazin-1-yl)pyrimidin-4-ylamino]-thiazol-5-yl}phenyl)urea (10a) as a potent inhibitor against unactivated and activated c-KIT. The binding of 10a induced rearrangements of the DFG motif, αC-helix, juxtamembrane domain, and the activation loop to switch the activated c-KIT back to its structurally inactive state. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.8b01845DOI Listing
April 2019
1 Read

Diagnosis and Treatment of Rectal Gastrointestinal Stromal Tumors.

Dis Colon Rectum 2019 May;62(5):537-540

Department of Surgery, University of Virginia, Charlottesville, Virginia.

Case Summary: A 69-year-old man presented with a rectal mass that was noted on physical examination. Flexible sigmoidoscopy confirmed the presence of a well-defined mass 3 cm from the anal verge (). Magnetic resonance imaging of the pelvis identified a 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DCR.0000000000001376DOI Listing
May 2019
3 Reads

Small gastrointestinal stromal tumour of the duodenum causing a life-threatening bleeding - A case report and review of the literature.

Int J Surg Case Rep 2019 Mar 30;57:160-162. Epub 2019 Mar 30.

Department of Abdominal surgery, University Medical Centre Ljubljana, Zaloška c. 7, 1000 Ljubljana, Slovenia. Electronic address:

Introduction: Duodenal gastrointestinal stromal tumors (DGISTs) are mesenchymal tumors. Main presenting symptoms are gastrointestinal bleeding and non-specific abdominal pain. Surgical treatment is golden standard for treatment of DGISTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2019.03.035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6454093PMC
March 2019
1 Read

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.

Int J Cancer 2019 Apr 8. Epub 2019 Apr 8.

University of Southern California/Norris Comprehensive Center, Los Angeles, CA.

Regorafenib 160 mg orally once daily (QD) 3 weeks on/1 week off is approved in colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. We established the safety and pharmacokinetics (PK) of regorafenib combined with cetuximab in advanced refractory solid tumors. This was a phase 1, open-label, dose-escalation study (NCT01973868) in patients with advanced/metastatic solid tumors who progressed after standard therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32317DOI Listing
April 2019
3 Reads

Potentiation of imatinib by cilostazol in sensitive and resistant gastrointestinal stromal tumor cell lines involves YAP inhibition.

Oncotarget 2019 Mar 5;10(19):1798-1811. Epub 2019 Mar 5.

Laboratory of Neurophysiology, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.

Despite the introduction of tyrosine kinase inhibitors, gastrointestinal stromal tumors (GIST) resistance remains a major clinical challenge. We previously identified phosphodiesterase 3A (PDE3A) as a potential therapeutic target expressed in most GIST. The PDE3 inhibitor cilostazol reduced cell viability and synergized with the tyrosine kinase inhibitor imatinib (Gleevec™) in the imatinib-sensitive GIST882 cell line. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26734DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442998PMC
March 2019
1 Read

Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre and Post-imatinib Eras.

Ann Surg 2019 Apr 2. Epub 2019 Apr 2.

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.

MINI: In the pre-imatinib era, primary tumor site, size, and mitotic rate predicted outcome as expected. In the modern era, survival was dramatically longer. While primary tumor high-risk features were associated with imatinib treatment, only tumor size >10 cm remained associated with outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SLA.0000000000003277DOI Listing
April 2019
3 Reads
8.327 Impact Factor

Fibromatosis - immunohistochemical evaluation, differential diagnosis from gastrointestinal tumors, and other mesenchymal tumours.

Prz Gastroenterol 2019 12;14(1):79-85. Epub 2019 Mar 12.

Department of Pathology, Jan Kochanowski University, Kielce, Poland.

Introduction: Fibromatosis is a histologically benign growth of fibroblastic and myofibroblastic cells, with a potential to recur and invade local organs. It can occur as a superficial or deep form. Visceral fibromatosis and superficial fibromatosis are histologically similar. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/pg.2019.83429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444105PMC
March 2019
5 Reads

Small intestinal perforation due to a huge gastrointestinal stromal tumor in a kidney transplant recipient: a case report and literature review.

BMC Nephrol 2019 Apr 3;20(1):120. Epub 2019 Apr 3.

Department of Urology, Keio University School of Medicine, Tokyo, 160-8582, Japan.

Background: Gastrointestinal stromal tumors (GISTs) in transplant recipients are very rare and only a handful of cases have been reported to date. Here we present the first known case of a huge GIST in a kidney transplant recipient with perforation of small intestine.

Case Presentation: A 64-year-old male presented at our hospital with right colic pain; he had received an ABO incompatible kidney transplant 6 years earlier and was treated with cyclosporine, mycophenolate mofetil, and methylprednisolone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12882-019-1310-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448240PMC
April 2019
3 Reads
1.520 Impact Factor

[Surgical treatment of neurofibromatosis type I followed by retroperitoneal tumor (in Russian only)].

Khirurgiia (Mosk) 2019 (3):5-14

Vishnevsky National Medical Research Center of Surgery, Moscow, Russia.

Aim: To determine the optimal surgical approach in patients with abdominal and retroperitoneal manifestations of Recklinghausen's disease.

Material And Methods: There were 4 patients (3 women and 1 man) with neurofibromatosis type I who were treated at Vishnevsky National Medical Research Center of Surgery.

Results: There were 3 robot-assisted procedures: excision of retroperitoneal tumors (plexiform neurofibroma and schwannoma) in 2 cases and right adrenal pheochromocytoma in 1 patient. Read More

View Article

Download full-text PDF

Source
http://www.mediasphera.ru/issues/khirurgiya-zhurnal-im-n-i-p
Publisher Site
http://dx.doi.org/10.17116/hirurgia20190315DOI Listing
January 2019
2 Reads

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome.

Cancers (Basel) 2019 Mar 25;11(3). Epub 2019 Mar 25.

GIST Team, Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan 333, Taiwan.

Background: Neoadjuvant imatinib therapy has been proposed for routine practice with favorable long-term results for patients with locally advanced gastrointestinal stromal tumors (GISTs). However, clarification of the optimal duration, safety, and oncological outcomes of neoadjuvant imatinib use before surgical intervention remains necessary.

Methods: We prospectively analyzed the treatment outcomes of 51 patients with locally advanced, nonmetastatic GISTs treated with neoadjuvant imatinib followed by surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11030424DOI Listing
March 2019
2 Reads

Tailored management of primary gastrointestinal stromal tumors.

Cancer 2019 Apr 1. Epub 2019 Apr 1.

Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Gastrointestinal stromal tumors (GISTs) are the most common human sarcoma and can form along the entire gastrointestinal tract. Over the last 20 years, considerable advances have been made in our understanding of the biology of GISTs. The advent of tyrosine kinase inhibitors has provided effective medical therapy for the first time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32067DOI Listing
April 2019
2 Reads

Evaluation of the result of single-incision laparoscopic surgery for gastrointestinal stromal tumors in the stomach.

Surg Case Rep 2019 Mar 29;5(1):50. Epub 2019 Mar 29.

Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.

Background: Single-incision laparoscopic surgery (SILS) has recently been used for the management of gastrointestinal stromal tumors (GIST). Here, the feasibility and effectiveness of SILS for GIST and indications for SILS according to tumor location were investigated.

Case Presentation: From July 2009 to May to 2013, a total of 14 patients underwent SILS for GIST. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40792-019-0605-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441062PMC
March 2019
1 Read

Noninvasive prediction model for diagnosing gastrointestinal stromal tumors using contrast-enhanced harmonic endoscopic ultrasound.

Dig Liver Dis 2019 Mar 26. Epub 2019 Mar 26.

Department of Internal Medicine, Yonsei University College of Medicine, 03722, Seodaemun-gu, Seoul, Republic of Korea; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea.

Background & Aims: Subepithelial tumors (SETs) are difficult to diagnose accurately without invasive pathological confirmation. We created a noninvasive prediction model for diagnosing gastrointestinal stromal tumors (GISTs) using contrast-enhanced harmonic endoscopic ultrasound (CEH-EUS).

Methods: We retrospectively reviewed 176 patients who underwent CEH-EUS from October 2011 to August 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dld.2019.02.017DOI Listing
March 2019
1 Read

Gastrointestinal stromal tumors (GISTs) with remarkable cystic change: a specific subtype of GISTs with relatively indolent behaviors and favorable prognoses.

J Cancer Res Clin Oncol 2019 Mar 28. Epub 2019 Mar 28.

Department of General Surgery, Zhongshan Hospital, Fudan University, NO. 180 Fenglin Road, Shanghai, 200032, China.

Purpose: Gastrointestinal stromal tumors (GISTs) are typically solid neoplasms with small cystic change detected occasionally but in rare instances may present predominantly as cystic lesions. The histopathologic features and prognoses of cystic GISTs (cGISTs) are poorly understood.

Methods: We herein reviewed 20 cGISTs resected or consulted in our institution from January 1, 2003 to December 31, 2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-02853-yDOI Listing
March 2019
1 Read

Feasibility of using computed tomography texture analysis parameters as imaging biomarkers for predicting risk grade of gastrointestinal stromal tumors: comparison with visual inspection.

Abdom Radiol (NY) 2019 Mar 28. Epub 2019 Mar 28.

Department of Pathology, Korea University Ansan Hospital, Korea University College of Medicine, 123 Jeokgeum-ro, Danwon-gu, Ansan, 15355, Republic of Korea.

Purpose: To evaluate the feasibility of using computed tomography texture analysis (CTTA) parameters for predicting malignant risk grade and mitosis index of gastrointestinal stromal tumors (GISTs), compared with visual inspection.

Method And Materials: CTTA was performed on portal phase CT images of 145 surgically confirmed GISTs (mean size: 42.9 ± 37. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-01995-4DOI Listing

Assessment of Duodenal Adenomas and Strategies for Curative Therapy.

Dig Dis 2019 Mar 28:1-7. Epub 2019 Mar 28.

Clinic for Gastroenterology and Hepatology, Clinical Center Serbia, Belgrade, Serbia.

Background: The increasing incidence of duodenal neoplasm has underlined different methods of resection depending on the clinical presentation, endoscopic features and histopathology. In this comprehensive review, we systematically describe the current knowledge concerning the diagnosis and management of duodenal adenomas (DAs) and discuss data considering all possible therapeutic approaches.

Summary: Among a variety of duodenal lesions, including neuroendocrine tumors and gastrointestinal stromal tumors, DAs present precancerous lesions of the duodenal papilla or non-ampullary region necessitating removal. Read More

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/496697
Publisher Site
http://dx.doi.org/10.1159/000496697DOI Listing
March 2019
3 Reads
1.832 Impact Factor

Mutational testing in gastrointestinal stromal tumor.

Authors:
Yu Wang Jerry Call

Curr Cancer Drug Targets 2019 Mar 26. Epub 2019 Mar 26.

The Life Raft Group, 155 US-46 Wayne, NJ 07470. United States.

Targeted treatment has become a major modality in cancer management. Such cancer drugs are generally designed to treat tumors with certain genetic/genomic makeups. Mutational testing prior to prescribing targeted therapy is crucial in identifying who can receive clinical benefit from specific cancer drugs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666190326123945DOI Listing
March 2019
1 Read

Treatment recommendations for small gastric gastrointestinal stromal tumors: positive endoscopic resection.

Scand J Gastroenterol 2019 Mar 24:1-6. Epub 2019 Mar 24.

a Department of Gastroenterology and Hepatology , General Hospital, Tianjin Medical University , Tianjin , China.

Objectives: To evaluate the safety and efficacy of endoscopic resection and discuss the treatment strategy of small gastric gastrointestinal stromal tumors (GISTs) less than 2 cm.

Material And Methods: The data of 713 patients, who underwent endoscopic submucosal dissection (ESD) for gastric submucosal tumors (SMTs), were retrospectively analyzed. We investigated the clinicopathological features and analyzed the risk potential of small gastric GISTs, and documented therapeutic and follow-up outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00365521.2019.1578405DOI Listing

[Imatinib and beyond-what is important for surgery?]

Chirurg 2019 Mar 21. Epub 2019 Mar 21.

Innere Klinik (Tumorforschung), Sarkomzentrum am Westdeutschen Tumorzentrum, Universitätsklinik Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Deutschland.

The treatment of gastrointestinal stromal tumors (GIST) has dramatically improved since the introduction of small molecule KIT proto-oncogene receptor tyrosine kinase inhibitors. Nevertheless, the cure of patients is still based on surgical treatment of the primary tumor. The chance of long-term tumor control by tyrosine kinase inhibitors (TKI) even in the metastatic setting also appears to be improved after achieving a surgical complete resection. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00104-019-0934-0
Publisher Site
http://dx.doi.org/10.1007/s00104-019-0934-0DOI Listing
March 2019
3 Reads

Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord.

Pharmacol Res 2019 May 19;143:86-96. Epub 2019 Mar 19.

Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, 147002, India. Electronic address:

Imatinib is a tyrosine kinase inhibitor and is used as a first line drug in the treatment of Philadelphia-chromosome-positive chronic myeloid leukaemia and gastrointestinal stromal tumors. Being tyrosine kinase inhibitor, imatinib modulates the activities of Abelson gene (c-Abl), Abelson related gene (ARG), platelet-derived growth factor receptor (PDGFR), FMS-like tyrosine kinase 3 (FLT3), lymphocyte-specific protein (Lck), mitogen activated protein kinase (MAPK), amyloid precursor protein intracellular domain (AICD), α-synuclein and the stem-cell factor receptor (c-kit). Studies have shown the role of imatinib in modulating the pathophysiological state of a number of disorders affecting brain and spinal cord such as Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis and spinal cord injury. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2019.03.014DOI Listing
May 2019
1 Read
4.408 Impact Factor

Contribution of Anoctamins to Cell Survival and Cell Death.

Cancers (Basel) 2019 Mar 19;11(3). Epub 2019 Mar 19.

Institut für Physiologie, Universität Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany.

Before anoctamins (TMEM16 proteins) were identified as a family of Ca-activated chloride channels and phospholipid scramblases, the founding member anoctamin 1 (ANO1, TMEM16A) was known as DOG1, a marker protein for gastrointestinal stromal tumors (GIST). Meanwhile, ANO1 has been examined in more detail, and the role of ANO1 in cell proliferation and the development of different types of malignomas is now well established. While ANO5, ANO7, and ANO9 may also be relevant for growth of cancers, evidence has been provided for a role of ANO6 (TMEM16F) in regulated cell death. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2072-6694/11/3/382
Publisher Site
http://dx.doi.org/10.3390/cancers11030382DOI Listing
March 2019
6 Reads

Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11.

Int J Cancer 2019 Mar 19. Epub 2019 Mar 19.

IBD Center, Laboratory of Gastrointestinal Immunopathology, Humanitas Clinical and Research Center, Milan, Italy.

Colorectal cancer (CRC) is one of the most malignant tumors worldwide. Stromal cells residing in the tumor microenvironment strongly contribute to cancer progression through their crosstalk with cancer cells and extracellular matrix. Here we provide the first evidence that CRC-associated lymphatic endothelium displays a distinct matrisome-associated transcriptomic signature, which distinguishes them from healthy intestinal lymphatics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32286DOI Listing
March 2019
3 Reads

Cinematic Rendering of Neurofibromatosis Type I Gastrointestinal Stromal Tumors.

Radiology 2019 May 19;291(2):298. Epub 2019 Mar 19.

From the Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD 21287.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019190104DOI Listing
May 2019
1 Read

Surgical management and outcomes of duodenal gastrointestinal stromal tumors.

Acta Gastroenterol Belg 2019 Jan-Mar;82(1):11-18

Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Background And Study Aims: This retrospective study purports to examine these characteristics and compare the surgical procedures available and appropriate for the treatment of patients affected by duodenal GISTs.

Patients And Methods: A retrospective examination of reports and studies carried out between May 2012 and March 2017, and covering patients with primary GISTs of the duodenum was performed using modules from the SPSS package. Comparisons of treatment effects resulting from the administration of two differential methods of surgical treatment namely pancreaticoduodenectomy (PD), and limited resection (LR), were effected on the reports of the GIST patients thus selected. Read More

View Article

Download full-text PDF

Source

Transperineal Excision of Rectal Gastrointestinal Stromal Tumor.

Surg Technol Int 2019 03 19;34. Epub 2019 Mar 19.

Sechenov First Moscow State Medical University, Moscow, Russia.

Gastrointestinal stromal tumors (GIST) of the rectum occur in approximately 4% of patients with rectal malignancies. Herein, we demonstrate a transperineal approach as a safe surgical technique for GISTs located anterior to the rectum. The proposed technique allows safe and effective excision of a tumor without disturbing the rectal anterior wall. Read More

View Article

Download full-text PDF

Source
March 2019
2 Reads

Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS-P WT GIST.

Genes Chromosomes Cancer 2019 Mar 19. Epub 2019 Mar 19.

Department of Specialized, Experimental and Diagnostic Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.

Gastrointestinal stromal tumors (GIST) lacking mutations in KIT/PDGFRA or RAS pathways and retaining an intact SDH complex are usually referred to as KIT/PDGFRA/SDH/RAS-P WT GIST or more simply quadruple WT GIST (~5% of all GIST). Despite efforts made, no recurrent genetic event in quadruple WT GIST has been identified so far. To further investigate this disease, we performed high throughput copy number analysis on quadruple WT GIST specimens identifying a recurrent focal gain in band 11q13. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22753DOI Listing
March 2019
1 Read

Performance of risk stratification systems for gastrointestinal stromal tumors: A multicenter study.

World J Gastroenterol 2019 Mar;25(10):1238-1247

Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China.

Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor type in the gastrointestinal system. Presently, various classification systems to prognosticate GISTs have been proposed.

Aim: To evaluate the application value of four different risk stratification systems for GISTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v25.i10.1238DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421238PMC
March 2019
2 Reads

[Expression and clinical significance of SSH1 in gastrointestinal stromal tumors].

Zhonghua Yi Xue Za Zhi 2019 Mar;99(10):754-757

Department of Minimally Invasive Surgery, Hernia and Abdominal Wall Surgery, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi 830000, China.

To investigate the correlations between the expression of the slingshot-1(SSH1) and the general clinicopathological factors in gastrointestinal stromal tumor (GIST) patients. Immunohistochemical staining was used to detect the expression of SSH1 protein in 96 gastrointestinal stromal tumors, and the correlations between expression level of SSH1 and general clinicopathological factors were analyzed. Totally, there were 96 cases of GIST patients (49 males and 47 males), with a mean age of (55. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0376-2491.2019.10.009DOI Listing
March 2019
2 Reads

Management of low rectal gastrointestinal stromal tumor with neoadjuvant therapy and transanal excision: a rare case report and review of the literature.

Int J Gen Med 2019 1;12:121-124. Epub 2019 Mar 1.

Third Department of Surgery, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece,

Background: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. However, rectal GISTs represent only 5% of this category. We report a case of a rectal GIST treated with local excision after neoadjuvant therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJGM.S193988DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402437PMC
March 2019
4 Reads

Preoperative assessment of malignant potential of gastrointestinal stromal tumor by dual-time-point 18F-fluorodeoxyglucose positron emission tomography imaging: Usefulness of standardized uptake value and retention index.

J Cancer Res Ther 2019 Jan-Mar;15(1):142-147

Department of Surgery, Division of Upper Gastrointestinal Surgery, Korea University College of Medicine, Seoul, Korea.

Background: To evaluate the usefulness of preoperative imaging with F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) for noninvasive risk assessment of gastrointestinal stromal tumor (GIST).

Materials And Methods: A retrospective review including 32 patients with pathologically proven GIST. Preoperative FDG-PET scan results including maximum standardized uptake values (SUVs) of the GISTs at 1 h postinjection (SUV1) were available for all tumors and SUVs at 2 h postinjection (SUV2) were available for 22 tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_1093_16DOI Listing
March 2019
1 Read

Discovered on gastrointestinal stromal tumor 1, a keystone in the diagnosis of extraintestinal gastrointestinal stromal tumors.

J Cancer Res Ther 2019 Jan-Mar;15(1):138-141

Department of Pathology, Kasturba Medical College, Manipal University, Mangalore, Karnataka, India.

Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract (GIT) but have a low incidence. Arising from the interstitial cells of Cajal, GISTs occur at different sites in the GIT with stomach being the most common. They can rarely be seen at sites outside the GIT such as omentum, retroperitoneum and are called as extraintestinal GISTs (EGIST). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcrt.JCRT_28_17DOI Listing
March 2019
1 Read

A clinical and surgical challenge: Retrorectal tumors.

J Cancer Res Ther 2019 Jan-Mar;15(1):132-137

Department of General Surgery, Health Science University, Umraniye Education and Research Hospital, Umraniye, Istanbul, Turkey.

Aims: Retrorectal tumors are rare, mostly benign tumors and named due to their localization. Diagnoses of these tumors are usually delayed because of nonspecific complaints and symptoms. Magnetic resonance imaging has beneficial uses both for diagnosis and treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0973-1482.183192DOI Listing
March 2019
1 Read

Malignancies associated with GIST: a retrospective study with molecular analysis of KIT and PDGFRA.

Langenbecks Arch Surg 2019 Mar 15. Epub 2019 Mar 15.

Department of Pathology, FAU Erlangen-Nürnberg, Erlangen, Germany.

Purpose: Gastrointestinal stromal tumors (GISTs) are the most common soft tissue tumors of the GI tract. Studies have been published reporting additional neoplasms in GIST patients. This study aimed to evaluate possible associations of mutation type, morphology, and clinical aspects of GISTs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00423-019-01773-2DOI Listing
March 2019
1 Read

Coincidental Detection of Gastrointestinal Stromal Tumors During Laparoscopic Bariatric Procedures-Data and Treatment Strategy of a German Reference Center.

Obes Surg 2019 Mar 14. Epub 2019 Mar 14.

Division of Bariatric Surgery, Clinic of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital, Liebigstrasse. 20, D-4015, Leipzig, Germany.

Introduction: Intraoperative pathologic findings during bariatric surgery are relatively rare. Gastrointestinal stromal tumors (GISTs) are commonly located in the stomach and account for < 1% of all neoplasms of the alimentary tract. Coincidental detection of GISTs during bariatric surgery has been reported around 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11695-019-03782-yDOI Listing

Defining Tumor Rupture in Gastrointestinal Stromal Tumor.

Ann Surg Oncol 2019 Mar 13. Epub 2019 Mar 13.

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.

Tumor rupture is an important risk factor predictive of recurrence after macroscopically complete resection of gastrointestinal stromal tumors (GISTs), and an indication for defined interval or even lifelong adjuvant therapy with imatinib according to guidelines. However, there is no consensus or universally accepted definition of the term 'tumor rupture', and, consequently, its incidence varies greatly across reported series. Without predefined criteria, the clinical significance of rupture has also been difficult to assess on multivariate analysis of retrospective data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-019-07297-9DOI Listing
March 2019
6 Reads

A Rare Case of Gastrointestinal Stromal Tumor with a Liver Metastasis Infiltrating the Inferior Vena Cava and Extending to the Right Atrium with an Early Recurrence after Surgical Extraction.

Case Rep Cardiol 2019 5;2019:2623403. Epub 2019 Feb 5.

Department of Cardiology, Dreifaltigkeits Hospital Lippstadt, Germany, Academic Teaching Hospital of Westfaelische Wilhelms University Muenster, Germany.

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract. The major cause of GIST is the presence of an abnormal form of tyrosine protein kinase (KIT) protein also known as CD117, which causes uncontrollable growth of the gastrointestinal cells. Most studies report incidences between 10 and 15 cases of GISTs per million. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/2623403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379877PMC
February 2019
2 Reads

Genomic aberrations in cell cycle genes predict progression of -mutant gastrointestinal stromal tumors (GISTs).

Clin Sarcoma Res 2019 5;9. Epub 2019 Mar 5.

Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45147 Essen, Germany.

Background: Activating mutations of the receptor tyrosine kinase are early events in the development of most gastrointestinal stromal tumors (GISTs). Although GISTs generally remain dependent on oncogenic during tumor progression, mutations alone are insufficient to induce malignant behavior. This is evidenced by -mutant micro-GISTs, which are present in up to one-third of normal individuals, but virtually never progress to malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13569-019-0112-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399846PMC
March 2019
2 Reads

The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors.

Gastric Cancer 2019 Mar 11. Epub 2019 Mar 11.

Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.

Background: Few reliable prognostic markers have been established despite elucidation of the molecular mechanisms of gastrointestinal stromal tumor (GIST) development. We evaluated F-box and WD repeat domain-containing 7 (FBXW7), a cell-cycle-regulating and tumor suppressor, in GISTs. We aimed to determine the clinical relevance of FBXW7 in GISTs and characterize the molecular mechanism of FBXW7 in a GIST cell line. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10120-019-00950-yDOI Listing
March 2019
2 Reads

Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors.

Ther Adv Med Oncol 2019 1;11:1758835919831902. Epub 2019 Mar 1.

Department of Pharmacy and Biotechnology, Via Irnerio 48, 40126 Bologna, Italy.

In recent years, growing research interest has focused on the so-called liquid biopsy. A simple blood test offers access to a plethora of information, which might be extremely helpful in understanding or characterizing specific diseases. Blood contains different molecules, of which circulating free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and extracellular vesicles (EVs) are the most relevant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835919831902DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399766PMC
March 2019
1 Read

Surgery for duodenal gastrointestinal stromal tumor: A systematic review and meta-analysis of pancreaticoduodenectomy versus local resection.

Asian J Surg 2019 Mar 8. Epub 2019 Mar 8.

Department of Hepatobiliary & Pancreatovascular Surgery, First Affiliated Hospital of Xiamen University, Xiamen, China.

The purpose of this study is to assess the clinical outcomes and prognostic factors for survival of patients with duodenal gastrointestinal stromal tumors (GIST) who underwent pancreaticoduodenectomy (PD) or local resection (LR). PubMed database was searched for relevant studies. A meta-analysis was performed with Review Manager 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.asjsur.2019.02.006DOI Listing
March 2019
1 Read

Minimally Invasive Small Bowel Cancer Surgery.

Surg Oncol Clin N Am 2019 04 24;28(2):273-283. Epub 2018 Dec 24.

Department of Surgery, Stanford University School of Medicine, 300 Pasteur Drive, H3680, Stanford, CA 94305, USA. Electronic address:

Small bowel malignancies are extremely rare. Surgical resection is often the mainstay of treatment with the extent of the operation depending on the type of tumor. Whereas neuroendocrine tumors and adenocarcinoma require lymph node resection, gastrointestinal stromal tumors do not typically metastasize to regional nodes and therefore need resection only. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.soc.2018.11.008DOI Listing
April 2019
1 Read

Large incidental gastrointestinal stromal tumors in a patient presenting with acutely symptomatic nephrolithiasis: A case report.

Radiol Case Rep 2019 May 26;14(5):555-560. Epub 2019 Feb 26.

Cooper University Hospital, Division of Body Imaging, Department of Radiology, 1 Cooper Plaza, Camden, NJ 08103, USA.

Gastrointestinal stromal tumors (GISTs) are rare mesenchymal neoplasms, representing approximately 1%-2% of all primary gastrointestinal malignancies. Incidental GISTs are often less than 1 cm when discovered and have been reported predominantly in obese patients undergoing surgery for other medical indications. We present the rare case of a large incidental GIST in a nonobese patient with acutely symptomatic nephrolithiasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radcr.2019.02.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393756PMC
May 2019
1 Read

Relative Factors Analysis of Imatinib Trough Concentration in Chinese Patients with Gastrointestinal Stromal Tumor.

Chemotherapy 2019 Mar 5;63(6):301-307. Epub 2019 Mar 5.

Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China,

Aims: Imatinib plasma trough levels (IM Cmin) have been reported to have a considerable clinical impact in patients with gastrointestinal stromal tumors (GISTs). We therefore have investigated the factors affecting IM plasma concentration in Chinese GIST patients.

Methods: IM Cmin in 190 patients with GIST who were taking IM were measured. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000493195DOI Listing
March 2019
4 Reads
1.554 Impact Factor